# KLOW Peptide Side Effects in the Research Literature > KLOW Peptide Side Effects in the Research Literature: the blend's adverse profile is uncharacterized. Cited component safety, the WADA and copper cautions, and the blue-tint question. The blend has no characterized safety profile. What the component literature and the regulatory record do say, set out plainly and cited. ## The short version KLOW peptide side effects, in the strict sense, are uncharacterized: the four-peptide blend has never been tested, so there is no measured safety profile for the mixture itself. What exists is thin component-level safety data, plus two hard regulatory facts that apply because of which peptides are in the vial. In plain terms: a tiny human study found intravenous BPC-157 well tolerated in two adults, and an old thymosin beta-4 trial in 40 volunteers showed no serious problems — but those are single components, not KLOW. The two facts you should not skip: TB-500 is on the anti-doping banned list, and the blend carries the most copper of any stack of its type because GHK-Cu dominates the vial. Community-reported side effects, kept clearly labeled as anecdotal, are listed on [the effects page](/effects). ## What the cited component safety record shows No safety data exist for the four-peptide blend. The component safety signals are limited and belong to single peptides. A 2025 first-in-human pilot found intravenous BPC-157 up to 20 mg in two healthy adults was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [17] — reassuring, but n=2. For the TB-500 arm, the strongest human safety data are again for the full-length native protein: a randomized, placebo-controlled Phase 1 study gave intravenous thymosin beta-4 to 40 healthy volunteers, daily for 14 days across four dose cohorts, with only infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events [13]. The broader assessment is cautionary. A 2026 Sports Medicine review of unapproved peptide therapies — listing TB-500 and BPC-157 — concludes that many show favorable animal-model outcomes but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [13]. None of these touches the blend. ## The WADA-prohibited arm and the angiogenesis caution Two cautions follow from which peptides the vial contains. First, anti-doping: TB-500 is the synthetic fragment of thymosin beta-4, which is named on the WADA Prohibited List under S2 (peptide hormones and growth factors), banned at all times in and out of competition [9]. Because TB-500 is one of the four components, using KLOW implicates anti-doping rules regardless of intent — a regulatory fact, not a theoretical risk [13]. Second, angiogenesis: three of the four components — BPC-157, TB-500 / thymosin beta-4 and GHK-Cu — promote new blood-vessel growth, BPC-157 through the VEGFR2-Akt-eNOS pathway [10]. Because solid tumors depend on new blood vessels for their supply, accelerating that growth is a theoretical concern flagged in the literature for anyone with an active or recent cancer [1]. No human study has tested this either way, for any component or for the blend; the caution is mechanistic, not a demonstrated clinical finding. ## Does the copper in GHK-Cu cause issues when blended with the other peptides? Copper(II) in GHK-Cu can engage in redox chemistry, a theoretical compatibility consideration when co-dissolved with the other peptides; this has not been formally characterized for the KLOW mixture [6]. Because GHK-Cu is the mass-dominant arm (about 50 of 80 mg), the blend also delivers more copper than most stacks of its type — a theoretical concern for anyone with a copper-handling disorder such as Wilson's disease [4]. ## Is KLOW peptide safe? No safety data exist for the four-peptide blend. Component safety signals are limited — a tiny 2025 IV BPC-157 pilot [17] and a 2010 IV thymosin beta-4 Phase 1 [13] — and a 2026 review notes scarce human safety data for unapproved musculoskeletal peptides and potential for serious harm [13]. Safety cannot be assumed from component data alone. ## What are the side effects of the KLOW peptide? Side effects of the blend are uncharacterized; no controlled study has measured them. Cited component safety is limited, and a 2026 musculoskeletal-peptide review warns of scarce human safety data and potential for serious harm outside regulatory oversight [13]. Community-reported effects — injection-site reactions, transient fatigue, mild headache — are anecdotal and listed on [the effects page](/effects). ## What are KLOW peptide benefits and side effects? Benefits are component-level extrapolations — the matrix (GHK-Cu), anti-inflammatory (KPV), tissue-repair (BPC-157) and wound-closure (TB-500) arms [4][3][2][1] — while side effects are uncharacterized for the blend. Component safety data are sparse, and the combination is unstudied and unapproved [13]. The two records, benefit and harm, are both incomplete for KLOW as a whole. --- An apothecary's quadripartite ledger of the four-peptide KLOW record — KPV, GHK-Cu, BPC-157 and TB-500 set out as four engraved specimen plates and weighed each against its own studies, the blend's column left ruled and blank because no controlled trial has filled it; no dispensary behind the page, no clinician in the name, and nothing here to dispense.